The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-Ll). In particular, the disclosed antibodies and fragments bind to human PD-Ll and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.La presente descripcion se refiere generalmente a anticuerpos y fragmentos de union funcionales de los mismos que se unen al ligando 1 de muerte programada (PD-L1)； en particular, los anticuerpos y fragmentos descritos se unen al PD-L1 de humano, y comprenden regiones determinantes de complementariedad (CDRs) novedosas； finalmente, la presente descripcion se refiere a administrar los anticuerpos y fragmentos descritos a sujetos con cancer, de esta manera tratando o retardando la progresion o proliferacion del cancer.
